Villar V - Search Results

1

Spred2 inhibits TGF-beta1-induced urokinase type plasminogen activator expression, cell motility and epithelial mesenchymal transition.

Villar V, Kocić J, Santibanez JF. Villar V, et al. Int J Cancer. 2010 Jul 1;127(1):77-85. doi: 10.1002/ijc.25045. Int J Cancer. 2010. PMID: 19908229 Free article.

2

ROS-NFkappaB mediates TGF-beta1-induced expression of urokinase-type plasminogen activator, matrix metalloproteinase-9 and cell invasion.

Tobar N, Villar V, Santibanez JF. Tobar N, et al. Among authors: villar v. Mol Cell Biochem. 2010 Jul;340(1-2):195-202. doi: 10.1007/s11010-010-0418-5. Epub 2010 Mar 5. Mol Cell Biochem. 2010. PMID: 20204677

3

SKIP is required for TGF-β1-induced epithelial mesenchymal transition and migration in transformed keratinocytes.

Villar V, Kocic J, Bugarski D, Jovcic G, Santibanez JF. Villar V, et al. FEBS Lett. 2010 Nov 19;584(22):4586-92. doi: 10.1016/j.febslet.2010.10.020. Epub 2010 Oct 19. FEBS Lett. 2010. PMID: 20965173 Free article.

4

Skip Regulates TGF- β 1-Induced Extracellular Matrix Degrading Proteases Expression in Human PC-3 Prostate Cancer Cells.

Villar V, Kocic J, Santibanez JF. Villar V, et al. Prostate Cancer. 2013;2013:398253. doi: 10.1155/2013/398253. Epub 2013 May 20. Prostate Cancer. 2013. PMID: 23766912 Free PMC article.

5

SKIP Downregulation Increases TGF-β1-Induced Matrix Metalloproteinase-9 Production in Transformed Keratinocytes.

Kocić J, Villar V, Krstić A, Santibanez JF. Kocić J, et al. Among authors: villar v. Scientifica (Cairo). 2012;2012:861647. doi: 10.6064/2012/861647. Epub 2012 Aug 2. Scientifica (Cairo). 2012. PMID: 24278749 Free PMC article.

6

The Metabolic Features of Tumor-Associated Macrophages: Opportunities for Immunotherapy?

Mojsilovic SS, Mojsilovic S, Villar VH, Santibanez JF. Mojsilovic SS, et al. Among authors: villar vh. Anal Cell Pathol (Amst). 2021 Aug 14;2021:5523055. doi: 10.1155/2021/5523055. eCollection 2021. Anal Cell Pathol (Amst). 2021. PMID: 34476174 Free PMC article. Review.

7

Current and Future Cancer Chemoprevention Strategies.

Santibanez JF, Villar VH, Echeverria C. Santibanez JF, et al. Among authors: villar vh. Pharmaceutics. 2023 May 19;15(5):1543. doi: 10.3390/pharmaceutics15051543. Pharmaceutics. 2023. PMID: 37242785 Free PMC article.

8

Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas.

Villar VH, Vögler O, Martínez-Serra J, Ramos R, Calabuig-Fariñas S, Gutiérrez A, Barceló F, Martín-Broto J, Alemany R. Villar VH, et al. PLoS One. 2012;7(5):e37735. doi: 10.1371/journal.pone.0037735. Epub 2012 May 25. PLoS One. 2012. PMID: 22662203 Free PMC article.

9

Oleanolic and maslinic acid sensitize soft tissue sarcoma cells to doxorubicin by inhibiting the multidrug resistance protein MRP-1, but not P-glycoprotein.

Villar VH, Vögler O, Barceló F, Gómez-Florit M, Martínez-Serra J, Obrador-Hevia A, Martín-Broto J, Ruiz-Gutiérrez V, Alemany R. Villar VH, et al. J Nutr Biochem. 2014 Apr;25(4):429-38. doi: 10.1016/j.jnutbio.2013.12.003. Epub 2013 Dec 31. J Nutr Biochem. 2014. PMID: 24491315

10

Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma.

Alemany R, Moura DS, Redondo A, Martinez-Trufero J, Calabuig S, Saus C, Obrador-Hevia A, Ramos R, Villar VH, Valverde C, Vaz MA, Medina J, Felipe-Abrio I, Hindi N, Taron M, Martin-Broto J. Alemany R, et al. Clin Cancer Res. 2018 Nov 1;24(21):5239-5249. doi: 10.1158/1078-0432.CCR-18-0851. Epub 2018 Jul 23. Clin Cancer Res. 2018. PMID: 30037815 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

162 results

Search Page